FEATURED NEWS

On the 30th July 2021 the Advisory Coalition on Vaccines said Guillain-Barre Syndrome should be listed as a possible side effect. Why isn’t it and other nervous disorders in the indemnity scheme?

Question Number: 106
PDR Number: SQ22-000163
Date Submitted: 24/02/2022
Department or Body: Department of Health

If this question relates to the COVID-19 Vaccine Claims Scheme, Guillain Barre Syndrome (GBS) is included as a recognised clinical condition related to Vaxzevria (Astra-Zeneca).

Regarding ‘the indemnity scheme’, the Commonwealth funds health professional indemnity support programs. These programs are generally not limited to practitioner negligence associated with any specific disorders, so there is no need to list particular conditions or nervous disorders. More information about Commonwealth indemnity programs is available at: www1.health.gov.au/internet/main/publishing.nsf/Content/medicalindemnity-iifs

Share:

Facebook
Twitter
Pinterest
LinkedIn

SENATE SPEECHES

THE ISSUES

Click on an interest area to read articles and learn more about the work I am doing in Parliament.

Taxation, Finance & Economy

READ MORE

Education & Family

READ MORE

Energy

READ MORE

Environment

READ MORE

Health, Aged Care & Seniors

READ MORE

Primary Industries

READ MORE

Immigration & Foreign Affairs

READ MORE

Infrastructure, Manufacturing, Transport & Tourism

READ MORE

Defence

READ MORE

Federation Reform

READ MORE

I may get kicked off social media soon for speaking too much truth so please join my mailing list so we can always stay in touch...

Thank you,

Gerard